Diclofenac and aceclophenac difference
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Searching the Web
aceclofenac vs diclofenac differences pharmacology COX selectivity GI safety
Here is a thorough comparison of diclofenac and aceclofenac:
Diclofenac vs Aceclofenac - Key Differences
Origin and Structure
| Feature | Diclofenac | Aceclofenac |
|---|---|---|
| Chemical class | Phenylacetic acid derivative | 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid derivative |
| Development | Older, established NSAID | Developed in 1991 as a chemical modification of diclofenac to improve GI tolerability |
| Structural difference | Parent compound | Aceclofenac is essentially diclofenac with a glycolamide ester group; it is partially converted to diclofenac (~20%) in vivo |
Mechanism of Action (COX Selectivity)
| Feature | Diclofenac | Aceclofenac |
|---|---|---|
| COX inhibition | Preferential COX-2 inhibitor (similar selectivity to celecoxib); inhibits both COX-1 and COX-2 | Preferential COX-2 inhibitor; has slightly greater COX-2 selectivity than diclofenac |
| COX-2 inhibition | High (~94% inhibition of COX-2 at therapeutic doses) | Comparable to or slightly higher than diclofenac |
| Additional IL-1 inhibition | Not prominent | Aceclofenac additionally inhibits IL-1 production, providing extra anti-inflammatory benefit beyond COX inhibition alone |
Pharmacokinetics (ADME)
| Feature | Diclofenac | Aceclofenac |
|---|---|---|
| Absorption | Rapid; first-pass effect ~50% bioavailability | Well absorbed orally; higher bioavailability (~F ~100% reported in some studies) |
| Half-life (t½) | Short: 1-2 hours | Slightly longer: ~4 hours |
| Protein binding | Extensive (>99%) | Extensive (~99%) |
| Metabolism | Liver (CYP2C subfamily); metabolites include 4-hydroxydiclofenac; excreted in urine (65%) and bile (35%) | Partially converted to diclofenac (~20%) and 4-hydroxydiclofenac in vivo; both drugs share metabolic pathways |
| Synovial penetration | Accumulates in synovial fluid; duration of action exceeds plasma t½ | Also penetrates synovial fluid well; slightly longer t½ means more sustained action |
| Dosing frequency | Typically 2-3 times daily (50 mg TDS or 75 mg BD) | Twice daily (100 mg BD) is standard |
Therapeutic Uses
Both drugs are used for:
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Acute pain, dysmenorrhea
Additional uses of diclofenac (not aceclofenac):
- Acute migraine (IV/powder formulations)
- Ophthalmic solution (post-cataract surgery, refractive surgery)
- Topical gel for actinic keratosis (3% formulation)
- Transdermal patch for minor musculoskeletal pain
Adverse Effects
| Feature | Diclofenac | Aceclofenac |
|---|---|---|
| GI adverse effects | Affects ~20% of patients; GI ulceration, bleeding, dyspepsia | Significantly lower GI incidence (~11% vs 15% for diclofenac in large observational studies; p<0.001) |
| Overall AE rate | ~27% in large studies | ~22% (significantly lower; p<0.001) |
| Hepatotoxicity | Notable risk - severe liver injury in 6-11 per 100,000 regular users annually; transaminase elevation (>3x ULN) in ~4% of patients; monitor LFTs during first 8 weeks | Less hepatotoxic data; lower conversion to reactive metabolites thought to reduce hepatotoxicity risk |
| Cardiovascular risk | Similar to COX-2 selective NSAIDs | Similar cardiovascular risk profile |
| Renal effects | Standard NSAID renal toxicity | Similar renal risk |
A large observational study (n=10,142) showed overall AEs were significantly lower with aceclofenac than diclofenac (22% vs 27%), with GI AEs also lower (11% vs 15%). A meta-analysis of 7 RCTs in osteoarthritis found a 31% lower risk of GI AEs with aceclofenac vs diclofenac/piroxicam (RR 0.69, 95% CI 0.57-0.83).
Formulations Available
| Diclofenac | Aceclofenac |
|---|---|
| Oral (immediate-release, sustained-release) | Oral tablets (100 mg) |
| IV injection | Not available IV |
| Topical gel (1%, 3%) | Topical gels available in some markets |
| Transdermal patch | Not standard |
| Ophthalmic solution | No ophthalmic formulation |
| Combination with misoprostol | Combinations with rabeprazole/pantoprazole common |
Summary: When to Prefer One Over the Other
- Prefer aceclofenac when GI tolerability is a concern (e.g., elderly patients, those with a history of GI upset), or when a twice-daily dosing schedule improves compliance. Its additional IL-1 inhibition may offer a small extra anti-inflammatory benefit.
- Prefer diclofenac when multiple formulations are needed (topical, ophthalmic, IV, or migraine preparations), or when cost and availability are concerns. It has a broader evidence base, more formulation variety, and is FDA-approved in the US (aceclofenac is more common in Europe and Asia, not approved by FDA).
- Hepatotoxicity monitoring is more strongly emphasized with diclofenac (LFTs in first 8 weeks of use); aceclofenac's lower production of reactive metabolites may confer a modest hepatic advantage.
Sources: - Goodman & Gilman's Pharmacological Basis of Therapeutics, pp. 229-237 | - Dove Medical Press review on aceclofenac GI safety
This is a shared conversation. Sign in to Orris to start your own chat.